Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Adenocarcinoma
/ epidemiology
Aspirin
/ therapeutic use
Case-Control Studies
Chemoprevention
Esophageal Neoplasms
/ epidemiology
Esophageal Squamous Cell Carcinoma
/ prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Metformin
/ therapeutic use
Proton Pump Inhibitors
/ therapeutic use
Retrospective Studies
Risk Factors
Aspirin
Chemoprevention
Medication
Oesophageal cancer
Risk stratification
Journal
Digestion
ISSN: 1421-9867
Titre abrégé: Digestion
Pays: Switzerland
ID NLM: 0150472
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
08
2021
accepted:
09
11
2021
pubmed:
21
12
2021
medline:
10
5
2022
entrez:
20
12
2021
Statut:
ppublish
Résumé
Oesophageal cancer comprises 2 different histological variants: oesophageal squamous-cell carcinoma (ESCC) and adenocarcinoma (EAC). While there are multiple therapeutic options for both types, patients with advanced or metastatic oesophageal cancer still suffer from poor prognosis. The study aimed to examine the association between the risk of oesophageal cancer and medications and to estimate the chemopreventive effects of commonly used drugs. A multicentre retrospective cohort study was conducted using data from 9 hospital databases of hospitalized patients between 2014 and 2019. The primary outcomes were ESCC and EAC. The association of oesophageal cancer with drug use and clinical factors was evaluated. Odds ratios (ORs) were adjusted for age, sex, Charlson comorbidity index scores, and smoking with/without gastro-oesophageal reflux disease. The use of proton pump inhibitors (PPIs) (adjusted OR [aOR] 0.48, p < 0.0001), aspirin (aOR 0.32, p < 0.0001), cyclooxygenase-2 inhibitor (COX2I) (aOR 0.70, p = 0.0005), steroid (aOR 0.19, p < 0.0001), statin (aOR 0.43, p < 0.0001), and metformin (aOR 0.42, p < 0.0001) was associated with a lower risk of ESCC than that in non-use. The use of aspirin (aOR 0.33, p = 0.0006) and steroids (aOR 0.54, p = 0.022) was associated with a lower risk of EAC than that in non-use. COX2Is, statins, metformin, and PPIs could help in prevention of ESCC, and aspirin and steroids may be chemopreventive for both types of oesophageal cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Oesophageal cancer comprises 2 different histological variants: oesophageal squamous-cell carcinoma (ESCC) and adenocarcinoma (EAC). While there are multiple therapeutic options for both types, patients with advanced or metastatic oesophageal cancer still suffer from poor prognosis.
AIMS
OBJECTIVE
The study aimed to examine the association between the risk of oesophageal cancer and medications and to estimate the chemopreventive effects of commonly used drugs.
METHODS
METHODS
A multicentre retrospective cohort study was conducted using data from 9 hospital databases of hospitalized patients between 2014 and 2019. The primary outcomes were ESCC and EAC. The association of oesophageal cancer with drug use and clinical factors was evaluated. Odds ratios (ORs) were adjusted for age, sex, Charlson comorbidity index scores, and smoking with/without gastro-oesophageal reflux disease.
RESULTS
RESULTS
The use of proton pump inhibitors (PPIs) (adjusted OR [aOR] 0.48, p < 0.0001), aspirin (aOR 0.32, p < 0.0001), cyclooxygenase-2 inhibitor (COX2I) (aOR 0.70, p = 0.0005), steroid (aOR 0.19, p < 0.0001), statin (aOR 0.43, p < 0.0001), and metformin (aOR 0.42, p < 0.0001) was associated with a lower risk of ESCC than that in non-use. The use of aspirin (aOR 0.33, p = 0.0006) and steroids (aOR 0.54, p = 0.022) was associated with a lower risk of EAC than that in non-use.
CONCLUSION
CONCLUSIONS
COX2Is, statins, metformin, and PPIs could help in prevention of ESCC, and aspirin and steroids may be chemopreventive for both types of oesophageal cancer.
Identifiants
pubmed: 34929693
pii: 000520924
doi: 10.1159/000520924
pmc: PMC9153329
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Proton Pump Inhibitors
0
Metformin
9100L32L2N
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
192-204Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
Int J Mol Sci. 2020 Jan 19;21(2):
pubmed: 31963924
Gut. 2004 Jan;53(1):12-20
pubmed: 14684569
Gastroenterology. 2000 Jan;118(1):36-47
pubmed: 10611152
Gut. 2018 Oct;67(10):1908-1910
pubmed: 29273641
Curr Cancer Drug Targets. 2004 Feb;4(1):29-42
pubmed: 14965265
Oncogene. 2016 Oct 13;35(41):5337-5349
pubmed: 26923327
Clin Gastroenterol Hepatol. 2013 Jun;11(6):620-9
pubmed: 23357487
Gastroenterology. 2016 Apr;150(4):854-65.e1; quiz e16-7
pubmed: 26775632
Gut. 2001 Mar;48(3):310-3
pubmed: 11171818
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
N Engl J Med. 2014 Aug 28;371(9):836-45
pubmed: 25162890
Lancet. 2018 Aug 4;392(10145):400-408
pubmed: 30057104
Curr Opin Pharmacol. 2016 Dec;31:31-37
pubmed: 27591354
Cell Mol Gastroenterol Hepatol. 2020;10(2):434-449.e1
pubmed: 32330731
CA Cancer J Clin. 2012 Mar-Apr;62(2):118-28
pubmed: 22281605
Oncotarget. 2017 Jan 3;8(1):203-214
pubmed: 27448962
World J Gastroenterol. 2015 Jul 14;21(26):7933-43
pubmed: 26185366
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003453
Eur J Cancer Prev. 2017 Jan;26(1):1-9
pubmed: 26886236
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Oncol Rep. 2017 Oct;38(4):1915-1922
pubmed: 28765919
Am J Gastroenterol. 2020 Jan;115(1):73-78
pubmed: 31821177
World J Gastroenterol. 2019 Jun 14;25(22):2706-2719
pubmed: 31235994
Gut. 2018 Jan;67(1):28-35
pubmed: 29089382
PLoS Med. 2021 Aug 2;18(8):e1003731
pubmed: 34339416
Dis Esophagus. 2011 Nov;24(8):544-9
pubmed: 21539676
South Med J. 2014 Dec;107(12):774-9
pubmed: 25502158
Nat Rev Cancer. 2016 Apr 26;16(5):305-18
pubmed: 27112208